Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015000LC2
Tue, 02.12.2025
Mainz BioMed N.V.
DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
DNA-based Colorectal Cancer Screening as a Home Test
BERKELEY, US, MAINZ and BERLIN, Germany – December 02, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer,today announced that [ … ]
Tue, 18.11.2025
Mainz BioMed N.V.
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador
BERKELEY, US and MAINZ, Germany – November 18, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Compa [ … ]
Wed, 12.11.2025
Mainz BioMed N.V.
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
BERKELEY, US and MAINZ, Germany – November 12, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of [ … ]
Mon, 10.11.2025
Mainz BioMed N.V.
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
BERKELEY, US and MAINZ, Germany – November 10, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announ [ … ]
Wed, 15.10.2025
Mainz BioMed N.V.
Mainz Biomed to Attend 2025 Maxim Growth Summit
BERKELEY, US and MAINZ, Germany – October 15, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place Oct [ … ]
Wed, 08.10.2025
Mainz BioMed N.V.
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95%
BERKELEY, US and MAINZ, Germany – October 8, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in [ … ]
Tue, 30.09.2025
Mainz BioMed N.V.
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
BERKELEY, US and MAINZ, Germany – September 30, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its particip [ … ]
Tue, 23.09.2025
Mainz BioMed N.V.
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Company Provides Update on eAArly DETECT 2 Study
BERKELEY, US and MAINZ, Germany – September 23, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to ann [ … ]
Tue, 02.09.2025
Mainz BioMed N.V.
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
BERKELEY, US and MAINZ, Germany – September 2, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration wit [ … ]
Wed, 13.08.2025
Mainz BioMed N.V.
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
BERKELEY, US and MAINZ, Germany – August 13, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal cancer (CRC) [ … ]
